Menari Group

Showing 1 posts of 1 posts found.

NICE recommendation for KORSERDU®▼ (elacestrant) marks ‘step-change’ in the treatment of ESR1-mutated metastatic breast cancer

December 19, 2024
ESR1, Menari Group, NICE, breast cancer, drug

Elacestrant is the first tailored treatment for certain people with oestrogen receptor (ER)-positive HER2-negative locally advanced and metastatic breast cancer …

The Gateway to Local Adoption Series

Latest content